Assay Report
Methods · Standard Curves · QC · Results
High-throughput Enzyme-Linked ImmunoSpot (ELISpot) and FluoroSpot screening services utilizing synthetic overlapping peptide libraries and two-dimensional peptide matrix pools (PepMix) to map immunodominant CD4+ and CD8+ T-cell epitopes in human, non-human primate (NHP), and rodent peripheral blood mononuclear cells (PBMCs) and splenocytes.
By quantifying antigen-specific IFN-γ, IL-2, and TNF-α spot-forming units (SFU) at single-cell resolution down to 1 in 1,000,000 cells, our epitope mapping platform accelerates neoantigen cancer vaccine discovery, viral epitope identification, and therapeutic biologic de-immunization.
Universal experimental design dimensions ensuring sound biological comparison and analytical specificity.
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Peptide Library Specifications | Synthetic 15-mers overlapping by 11 amino acids spanning entire target protein sequence (>90% purity) | Ensures complete, gap-free representation of all possible linear CD4+ and CD8+ T-cell epitopes across diverse HLA types. |
| 2D Matrix Pool Layout | Orthogonal N × M intersecting matrix grid (e.g., 10 × 10 grid testing 100 peptides in only 20 pools) | Maximizes screening throughput while dramatically reducing required donor PBMC volume. |
| Control Arm Configuration | Negative control (DMSO/media <5 SFU/well), Positive control (phytohemagglutinin [PHA] >500 SFU/well), Recall control (CEFX viral pool) | Guarantees analytical specificity, confirms baseline PBMC viability, and establishes background noise thresholds. |
| Secondary Deconvolution Step | Focused secondary ELISpot assay testing individual candidate peptides identified at matrix intersections | Validates true single-peptide immunogenicity and eliminates false-positive bystander activations. |
| Minimal Epitope Truncation | Systematic N- and C-terminal truncation (8-mer to 11-mer) and alanine scanning mutagenesis | Defines the minimal essential binding core and identifies critical contact residues for TCR/MHC interaction. |
Validated ELISpot mapping configurations across cancer neoantigens, viral proteomes, and biotherapeutic scaffolds.
| Target Class & Application Focus | Peptide Library & Matrix Configuration | Primary Detection Endpoint | Dedicated Research Application |
|---|---|---|---|
| Neoantigen Vaccine Epitope Screening | Patient-specific predicted neoepitope peptide matrices | IFN-γ & IL-2 Spot-Forming Units (SFU) | Validating in silico predicted tumor neoantigens for personalized mRNA and peptide cancer vaccines. |
| Viral Proteome Immunodominance Mapping | Full viral proteome overlapping peptide libraries (SARS-CoV-2, CMV, EBV, RSV, Influenza) | High-throughput IFN-γ spot enumeration | Identifying protective cross-reactive T-cell targets across emerging viral variants and vaccine candidates. |
| Biotherapeutic De-Immunization Screening | Overlapping peptides across therapeutic mAbs, ADCs, enzymes, and Cas9 nucleases | CD4+ helper T-cell response mapping | Identifying and mutating immunogenic T-cell epitopes to reduce clinical anti-drug antibody (ADA) incidence. |
| Cancer-Testis & Tumor-Associated Antigens | NY-ESO-1, MAGE-A3, WT1, PRAME, HER2 peptide libraries | Dual IFN-γ / Granzyme B FluoroSpot | Screening baseline and post-treatment T-cell responses in TCR-T and adoptive cellular therapy trials. |
| Minimal Epitope & Alanine Scanning | Fine truncation series (8–11 mers) and single amino acid substitutions | Binding affinity & SFU drop curves | Defining exact core contact residues and MHC anchor motifs for structural TCR-pMHC modeling. |
Evaluating throughput, cell consumption, and epitope discovery efficiency across cellular platforms.
| Technical Dimension | 2D Matrix ELISpot (Our Service) | Flow Cytometry Intracellular Cytokine Staining (ICS) | MHC Multimer / Dextramer Staining |
|---|---|---|---|
| Primary Utility | High-throughput de novo epitope discovery | Phenotyping known responsive subsets | Tracking known single epitope clones |
| HLA Restriction Requirement | Unbiased (Works across all HLA alleles) | Unbiased | Strict (Requires pre-matched HLA alleles) |
| Frequency Sensitivity (LOD) | 1 in 100,000 to 1 in 1,000,000 | ~1 in 1,000 (Low sensitivity) | ~1 in 10,000 |
| PBMC Input for 100 Peptides | 2–4 × 10^6 viable PBMCs | 20–50 × 10^6 PBMCs | 10–20 × 10^6 PBMCs |
| Living Secretory Readout | Yes (Active cytokine secretion) | No (Trapped intracellularly) | No (Binding only; non-functional) |
| Secondary Deconvolution | Rapid single-peptide confirmation | Labor intensive | Complex multi-reagent setup |
Standardized operating procedures, automated spot deconvolution, and rigorous quality gating.
Synthetic 15-mer peptide libraries synthesized at >90% purity, validated by HPLC and mass spectrometry, and formulated with minimal DMSO to prevent toxicity.
Proprietary mathematical algorithms cross-reference row and column spot counts to accurately rank candidate intersecting peptides with minimal false positives.
Every candidate identified at matrix pool intersections is validated in a secondary focused single-peptide assay to confirm minimal immunogenic epitopes.
Generating overlapping 15-mer peptide sequences and formulating 2D row/column matrix pools.
Controlled thawing of cryopreserved donor PBMCs with Benzonase; 18-hour resting at 37°C.
Plating viable PBMCs with matrix pools, positive controls, and DMSO negative controls in anti-IFN-γ PVDF plates.
Reader acquisition, spot enumeration, and bioinformatic identification of intersecting candidate peptides.
Testing identified individual candidate peptides to validate minimal immunogenic epitopes and deliver final mapping dossiers.
Standardized cell handling protocols ensuring robust T-cell activation across large screening matrices.
| Pre-Analytical Parameter | Why It Matters for High-Throughput Epitope Screening | Intake Specification & Recommendation |
|---|---|---|
| PBMC Isolation Timing | Delayed separation of whole blood causes granulocyte activation and blunted T-cell responses. | Isolate PBMCs via density gradient centrifugation (Ficoll-Paque) within 8 hours of blood collection. |
| Cryopreservation Quality | Suboptimal freezing protocols damage fragile memory T-cell subsets, leading to false-negative mapping results. | Resuspend in pre-chilled freezing medium (90% FBS + 10% DMSO or CryoStor CS10); freeze at -1°C/min. |
| Post-Thaw Cell Viability | Dying cells release DNA and non-specific proteases, increasing background noise and suppressing antigen-specific activation. | Cell viability must exceed 80%; include a 1–2 hour recovery resting phase at 37°C prior to plating. |
| Input Cell Quantity | Multi-pool matrix screening requires sufficient cell aliquots across replicate wells. | Provide minimum 10–20 × 10^6 cryopreserved viable cells per donor/antigen screen. |
| Peptide Solubilization | Excess DMSO in working wells causes non-specific cellular toxicity and false-negative spot inhibition. | Reconstitute peptide pools in sterile DMSO/PBS; ensure final in-well DMSO concentration is strictly <0.25% v/v. |
Applying epitope mapping ELISpot across neoantigen vaccines, viral proteome screening, and protein de-immunization.
Screen patient-specific predicted neoepitopes to select immunogenic peptides for clinical mRNA and peptide vaccine formulation.
Identify conserved, cross-reactive CD4+ and CD8+ T-cell epitopes across emerging viral variants (Influenza, Coronaviruses).
Map helper T-cell epitopes in engineered antibody scaffolds and enzyme therapeutics to eliminate clinical ADA risks.
Identify novel tumor-associated antigen (TAA) epitopes to support TCR cloning and adoptive cell therapy engineering.
Map autoreactive T-cell epitopes in multiple sclerosis (MBP/MOG), Type 1 diabetes (insulin/GAD65), and arthritis models.
Map immunodominant capsid epitopes across natural and novel engineered AAV serotypes (AAV Capsid Immunogenicity).
Standardized bioanalytical documentation, annotated spot images, and senior immunologist consultation.
Key peer-reviewed publications establishing 2D matrix pooling principles and neoantigen vaccine validation.
Study Design Takeaway: Establishes the foundational two-dimensional matrix pooling methodology for high-throughput T-cell epitope mapping using minimal PBMC inputs.
Study Design Takeaway: Demonstrates the clinical utility of peptide ELISpot assays to validate in silico predicted neoantigen immunogenicity in personalized cancer vaccine trials.
Study Design Takeaway: Uses comprehensive overlapping peptide pools and ELISpot to map conserved, cross-reactive CD4+ T-cell epitopes across related human coronaviruses.
Study Design Takeaway: Details standardized operating procedures for in vitro antigen presentation, peptide pulsing, and single-cell spot quantification.
Addressing common project planning, cell handling, and assay selection inquiries.
2D matrix pooling organizes peptides into intersecting row and column pools (e.g., a 10×10 grid evaluates 100 peptides in only 20 wells). This reduces required donor PBMC volume by up to 80% while retaining the sensitivity to identify individual immunogenic peptides at the pool intersections.
The standard format is 15-mer synthetic peptides overlapping by 11 amino acids. This ensures that all potential 8–10-mer MHC Class I (CD8+) and 12–16-mer MHC Class II (CD4+) linear epitopes are fully represented.
Yes. Overlapping 15-mer peptide pools stimulate both CD4+ helper T cells (via MHC Class II presentation) and CD8+ cytotoxic T cells (via cross-presentation or direct MHC Class I binding). Follow-up CD4/CD8 magnetic bead depletion can be incorporated to confirm subset restriction.
For a library of 100 peptides using a 2D matrix design with duplicate wells and controls, we typically recommend providing 10–15 × 10^6 cryopreserved viable PBMCs.
In Step 2 of our service, we perform a focused secondary deconvolution ELISpot assay testing the individual candidate peptides identified at the intersections to confirm single-peptide immunogenicity and determine exact SFU frequencies.
No. All bioanalysis services provided by Creative Proteomics are strictly for Research Use Only (RUO). They are intended for preclinical discovery, neoantigen validation, vaccine design, and translational research cohorts, and are not intended for clinical diagnostic or patient management procedures.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×